- Home
- SRFM vs ANTX Comparison
SRFM vs ANTX Comparison
Compare SRFM & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRFM | ANTX |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 123.3M | 135.4M |
| IPO Year | 2023 | 2022 |
Fundamental Metrics
Financial Performance| Metric | SRFM | ANTX |
|---|---|---|
| Price | $1.32 | $3.98 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $3.25 | $2.00 |
| AVG Volume (30 Days) | 2.0M | ★ 3.3M |
| Earning Date | 03-12-2026 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.69 | 32.56 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $106,557,000.00 | N/A |
| Revenue This Year | $10.33 | N/A |
| Revenue Next Year | $66.62 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.34 | $1.00 |
| 52 Week High | $9.35 | $6.91 |
Technical Indicators
Market Signals| Indicator | SRFM | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 24.15 | 60.80 |
| Support Level | N/A | $1.05 |
| Resistance Level | $2.20 | $6.91 |
| Average True Range (ATR) | 0.15 | 0.90 |
| MACD | -0.05 | 0.03 |
| Stochastic Oscillator | 1.15 | 49.70 |
Price Performance
Historical ComparisonAbout SRFM Surf Air Mobility Inc.
Surf Air Mobility Inc provides a regional air mobility platform to connect communities sustainably. The company is an electric aviation and air travel company expanding the category of regional air travel and reinventing flying through electrification. The company is building a regional air mobility ecosystem to sustainably connect the world's communities. It generates revenue through air mobility services.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.